Journals / Journal of Clinical Research in Pediatric Endocrinology / 2016 / Cilt: 8 - Sayı: 3

Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results

Pages
288–297
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On the other hand, it was shown that INH-A could be used as a new diagnostic biomarker in addition to AMH.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Polycystic ovary syndrome (PCOS) is a common endocrine problem in adolescents with an increasing prevalence of 30%.
📊
Key Findings & Data:We aimed to investigate the diagnostic value of anti-Müllerian hormone (AMH), insulin-like peptide-3 (INSL3), inhibin-A (INH-A), and inhibin-B (INH-B) in adolescents with PCOS and also to determine the association, if any, between these hormones and clinical/laboratory findings related with hyperandrogenism.Methods: The study group comprised 53 adolescent girls aged between 14.5 and 20 years who were admitted to our outpatient clinic with symptoms of hirsutism and/or irregular menses and diagnosed as having PCOS in accordance with the Rotterdam criteria.
💡
Conclusion & Impact:On the other hand, it was shown that INH-A could be used as a new diagnostic biomarker in addition to AMH.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Polycystic ovary syndrome (PCOS) is a common endocrine problem in adolescents with an increasing prevalence of 30%. Pursuing new biomarkers with high specificity and sensitivity in the diagnosis of PCOS in adolescents is currently an active area of research. We aimed to investigate the diagnostic value of anti-Müllerian hormone (AMH), insulin-like peptide-3 (INSL3), inhibin-A (INH-A), and inhibin-B (INH-B) in adolescents with PCOS and also to determine the association, if any, between these hormones and clinical/laboratory findings related with hyperandrogenism.Methods: The study group comprised 53 adolescent girls aged between 14.5 and 20 years who were admitted to our outpatient clinic with symptoms of hirsutism and/or irregular menses and diagnosed as having PCOS in accordance with the Rotterdam criteria. Twenty-six healthy peers, eumenorrheic for at least two years and body mass index-matched, constituted the controls. Fasting blood samples for hormones [luteinizing hormone (LH), follicle-stimulating hormone (FSH), dehydroepiandrosterone-sulfate (DHEAS), androstenedione (D4-A), total/free testosterone (T/fT), sex hormone binding globulin (SHBG), AMH, INSL3, INH-A, INH-B] were drawn after an overnight fast. Results: In the PCOS group, 83% of the subjects were oligomenorrheic/amenorrheic and 87% had hirsutism. The LH, LH/FSH ratio, total T, fT, free androgen-index (FAI), DHEAS levels were significantly higher (p=0.005, p=0.042, p=0.047, p<0.001, p=0.007, p=0.014, respectively) and SHBG was significantly lower (p=0.004) in PCOS patients as compared to the controls. Although the INSL3 and INH-B levels showed no difference between the groups (p>0.05), AMH and INH-A levels were found to be significantly higher in the PCOS group compared to the controls (p<0.001, p<0.001, respectively). In multiple linear regression analysis, WC SDS (p=0.028), logD4-A (p=0.033), logSHBG (p=0.031), and total ovarian volume (p=0.045) had significant effects on AMH levels, and LH (p=0.003) cells in men (9). In women, it is synthesized in the ovary, particularly by the theca interna cells of antral follicles as well as by the corpora lutea and ovarian stroma, and INSL3 levels seem to reflect gonadal function (10,11). INSL3 levels are similar in prepubertal and postpubertal periods, but a significant increase is observed after pubertal onset (12). Some studies show that INSL3 expression appears on INH-A levels. In receiver-operating characteristic analysis, the cut-off values for AMH and INH-A were 6.1 ng/mL (sensitivity 81.1%) and 12.8 pg/mL (sensitivity 86.8%), respectively, to diagnose PCOS. When AMH and INH-A were used in combination, the sensitivity (96.2%) increased. Conclusion: INSL3 and INH-B were not found to have diagnostic value in adolescents with PCOS. On the other hand, it was shown that INH-A could be used as a new diagnostic biomarker in addition to AMH.

🔖

Cite This Article

ŞAHİN, A. Y., YETİM, Ç., BAŞ, F., EROL, O. B., ÇIĞ, G., UÇAR, A., DARENDELİLER, F. F. (2016). Anti-Müllerian Hormone and Inhibin-A, but not Inhibin-B or Insulin- Like Peptide-3, may be Used as Surrogates in the Diagnosis of Polycystic Ovary Syndrome in Adolescents: Preliminary Results. Journal of Clinical Research in Pediatric Endocrinology, Cilt: 8 - Sayı: 3, 288–297. https://ajindex.com/articles/270494

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar- Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO; ESE PCOS Special Interest Group. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:1-29. Epub 2014 May 21 Hickey M, Sloboda DM, Atkinson HC, Doherty DA, Franks S, Norman RJ, Newnham JP, Hart R. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab 2009;94:3714-3720. Epub 2009 Jun 30 Hart R, Doherty DA, Mori T, Huang RC, Norman RJ, Franks S, Sloboda D, Beilin L, Hickey M. Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 2011;95:2347-2353. Epub 2011 Mar 29 Isabel-Bouzas IC, Cader SA, Leao L, Kuschnir MC, Braga C. Menstrual cycle alterations during adolescence: early expression of metabolic syndrome and polycystic ovary syndrome. J Peadiatr Adolesc Gynecol 2014;27:335-341. Epub 2014 Sep 23 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reprod 2004;19:41-47.
  2. İliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. J Clin Endocrinol Metab 2013;98:3332- 3340. Epub 2013 Jun 17 Warren-Ulanch J, Arslanian S. Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab 2006;20:311-330.
  3. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK; Endocrine Society. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4565-4592. Epub 2013 Oct 22 Foresta C, Bettella A, Vinanzi C, Dabrilli P, Meriggiola MC, Garolla A, Ferlin A. A novel circulating hormone of testis origin in humans. J Clin Endocrinol Metab 2004;89:5952- 5958. Nichols N, Binta H, Fields PA, Drost M, Chang SM, Ivell R, Fields MJ. Immunohistochemical localization of relaxin-like factor/insulin-like peptide-3 in the bovine corpus luteum. Ann NY Acad Sci 2005;1041:506-509.
  4. Bamberger AM, Ivell R, Balvers M, Kelp B, Bamberger CM, Riethdorf L, Löning T. Relaxin-like factor (RLF): a new specific marker for Leydig cells in the ovar